Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Condition: Lymphoma Intervention: Biological: PCV20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Lymphoma | Meningitis Vaccine | Pneomococcal Vaccine | Research | Vaccines